Atara Biotherapeutics adopts Third Amended and Restated Bylaws with governance changes

Atara Biotherapeutics, Inc.

Board approved revised bylaws effective Dec 20, 2024; includes rights to postpone/cancel special stockholder meetings.
Grants Board exclusive use of white proxy card; enhances chair's authority over meeting conduct.
Tightens disclosure and procedural requirements for stockholder proposals and director nominations.
Adds severability clause and other administrative updates.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Atara Biotherapeutics, Inc.: Board approved Third Amended and Restated Bylaws with principal revisions including additional rights to postpone/reschedule special meetings, exclusive use of white proxy card for the Board, meeting conduct rules, stockholder proposal disclosure and procedural requirements, director eligibility req (effective 2024-12-20).

Change: bylaw amendment
Effective: 2024-12-20

Exact text from the filing

On December 20, 2024, the Board of Directors (the “ Board ”) of Atara Biotherapeutics, Inc., a Delaware corporation (the “ Company ”), approved the amendment and restatement of the Bylaws of the Company (the “ Third Amended and Restated Bylaws ”).

View on SEC.gov

190 governance changes filed in the last 30 days. Browse all governance changes →

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-284167

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.